Summary. Monoclonal antibodies (MAbs) N-59 and RU-1 were produced by immunisation of mice with streptokinase secreted by Streptococcus group A, type 12, strain A374 isolated from a patient with post-streptococcal glomerulonephritis (PSGN) and were characterised by Western blot analysis. MAb N-59 recognised antigenic determinants shared by both nephritis strain-associated streptokinase (NSA-SKase) and streptokinase of Streptococcus group C (C-SKase) ; MAb RU-1 reacted only with NSA-SKase. All nephritis-associated group A streptococcal strains tested reacted with MAb N-59; 87.5% of these strains reacted with MAb RU-1. MAb N-59 reacted with SKase produced by group G streptococcal strains isolated from patients with PSGN, and MAb RU-1 recognised SKase in two out of three of these strains.
Introduction
It has been reported that group A streptococci isolated from patients with post-streptococcal glomerulonephritis (PSGN) produce an extracellular protein that has a subunit of 46 Kda, as determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). This protein (not secreted generally by streptococcal strains isolated from patients without PSGN) was called the nephritis strain-associated protein (NSAP). 'Subsequently, the amino-acid composition and the first 21 N-terminal amino-acid sequence analysis of NSAP demonstrated that this molecule was streptokinase, but antigenically it proved to be different from the streptokinase of group C streptococci.
In this paper, NSAP is designated nephritis strainassociated SKase (NSA-SKase) and its presence was investigated in the supernates of cultures of group A, B, C and G streptococci, isolated from patients with or without PSGN, by Western blot analysis with monoclonal antibodies (MAbs) prepared against NSA-SKase.
Materials and methods
Strain A 374, a streptococcus of group A, type M12, was used as the standard strain for NSA-SKase i~olation.~ All of these strains were pharyngeal isolates from patients.
Extraction of extracellular products
Bacterial strains were grown in a chemically defined medium4 at 37°C and 10-ml samples were removed at different times during growth (4, 6, 8, 10, 12, 18 and 24 h). Cells were removed by centrifugation, and the proteins in the supernate were precipitated by the addition of cold trichloroacetic acid (TCA) as described previously. After centrifugation, TCA-precipitated pellets were washed with cold ethanol 95% containing 2~ sodium acetate 5%v/v. The pellets were suspended in distilled water and the proteins were separated by SDS-PAGE.' NSA-SKase, which has a M, of 46 Kda, appeared after growth for 6-8 h and then appeared to break down after 8 h (data not shown). Therefore, in the present studies, cultures were grown for 8 h only. Production of MAb to NSA-SKase BALB/c mice were given an initial intraperitoneal (i.p.) injection of 250 pg of extracellular products (ECP) of strain A374 emulsified in Freund's incomplete adjuvant (FICA) (Difco). They were then given 250-pg of ECP with FICA by i.p. injection each week for 4 weeks. After the last injection, they were given an intravenous injection of 500pg of ECP alone. Three days later, spleen cells were removed and spleen cell-myeloma cell (NS-1) hybrids were prepared. The supernates of hybridoma cells were assayed by enzymelinked immunosorbent assay with an electrophoretically purified NSA-SKase preparation3 and the MAb immunoglobulin (Ig) subclasses were determined by double immunodiffusion techniques with commercially prepared subclass-specific antisera (Serotec Ltd, Bicester). One hybridoma used in this study was designated N-59; the other, designated RU-1, was prepared as described previously. Both MAbs were of IgGl subclass.
Pur@ca t ion of NSA -SKase

Iso-electric focusing
Purified NSA-SKase was iso-electric focused in a thin layer of Sephadex IEF gel at 30 W for 6 h, with pH range 3.0-10, in the flat bed apparatus FBE 3000 according to the Pharmacia Instruction Manual. The sample (15 pl) was loaded on to the gel with an applicator and a broad PI callibration kit was used as standard markers.
SKase activity
SKase activity was assayed by fibrin clot resolving activity. SKase and reference SKase (Lederle Laboratories, Pearl River, NY, USA) were added to human euglobulin solution (as plasminogen source). Bovine fibrinogen (Miles Scientific, Naperville, IL, USA) and thrombin (Mochida Pharmaceutical Co., Tokyo, Japan) were added to the above mixture, and clots were incubated for 10 min in a water-bath at 37°C. A unit of SKase activity was defined as the amount of SKase that lysed the fibrin clot in 10 min. 4-78. Lane E shows group C streptokinase (C-SKase) (Sigma) isolated from strain H46A, Streptococcus equisimilis. The heavy band in lane E is human serum albumin used as a stabiliser. NSA-SKase from the chromatofocusing column had SKase activity (26 243 U/mg) and its activity was 230-fold greater than the SKase activity of the original ECP of strain A374.
Results and discussion
In Western blot analysis with two MAbs (N-59 and RU-1) as immunological probes, MAb N-59 reacted with both NSA-SKase from strain A374 and C-SKase ( fig. 2, lanes 3 and 4) , but MAb RU-1 reacted only with NSA-SKase ( fig. 2, lanes 1 and 2) . These results suggest that NSA-SKase has at least two antigenic domains. MAb N-59 recognised the same epitope, which is shared by both NSA-SKase and C-SKase, whereas the NSA-SKase-specific epitope reacted with MAb RU-1. Therefore, NSA-SKase possesses antigenic domains different from those present in cSKase. Johnston and Zabriskie2 reported that there were antigenic differences between NSA-SKase and C-SKase, and the presence of different epitopes in NSA-SKase and C-SKase was further confirmed by the use of MAbs.
Strains of group A(75), group B(4), group C(6) and group G (11) streptococci were analysed for the presence of NSA-SKase in TCA-precipitated pellets with MAbs N-59 and RU-1 in Western blot analysis (table I) . These strains were selected at random from clinical laboratory isolates. However, it was not clear whether these strains had been isolated from patients with PSGN. Out of the 96 strains of groups A, B, C and G streptococci, 68 (7043%) reacted with MAb N-59. However, only 26 (27.1%) strains reacted with both MAbs N-59 and RU-1. Two out of 11 group G streptococcal strains also reacted with both MAbs.
In the experiments to detect the presence of NSASKase in streptococcal strains isolated from welldocumented cases of PSGN, all of 16 group A streptococcal strains reacted with MAb N-59 (table 11) . MAb RU-1 reacted with only 14 (87.5%) of fig. 3 . After SDS-PAGE, the NSA-SKase contained in TCAprecipitated pellets was detected by both MAbs N-59 and RU-1. Lanes A-D and F-I show the TCAprecipitated pellets from strains isolated from patients without and with PSGN, respectively. Lane E contained NSA-SKase purified from strain A374 ( fig. 3,  I ). MAb RU-1 reacted only with NSA-SKase from strains isolated from patients with PSGN.
Although strains non-reactive with MAb N-59 were cultured for 2-24 h at 37"C, they failed to secrete SKase which would react with MAb N-59 in culture supernates. It is unclear why three strains (two of group A and one of group G) isolated from the pharynges of patients with PSGN were unable to secrete NSA-SKase in culture supernates that would react with MAb RU-1. However, 87.5% (14 out of 16) of strains of group A and 67% (2 out of 3) of strains of group G streptococci isolated from patients with PSGN secreted NSA-SKase in culture supernates. Thus, the production of NSA-SKase is associated closely with the development of PSNG and it is interesting that NSA-SKase is produced from group G streptococcal strains isolated from patients with PSGN.
In group A, streptococcal strains isolated from patients with PSGN strains of types 4 and 12 secreted NSA-SKase at high frequency. However, strains of other types also secreted NSA-SKase. Therefore, the production of NSA-SKase by streptococci appears to be strain-rather than type-specific (tables I and 11).
